Trastuzumab Biosimilar on Track for Approval.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-115
Abstract: An FDA expert panel recommended approval of Mylan's MYL-14010, a biosimilar candidate for Genentech's trastuzumab, putting it on track to become the first approved biosimilar for cancer. Experts predict that biosimilars will lead to lower… read more here.
Keywords: track; track approval; biosimilar track; trastuzumab biosimilar ... See more keywords